Our vision

• All the holding’s activities are aimed at achieving a leading position in the production of hyaluronan, the raw material used primarily in the pharmaceutical industry and cosmetics. The strategic objective is to manufacture final pharmaceutical products based on various polysaccharides, especially hyaluronan in original and modified form.
  
• The holding also places a great emphasis on the development of its customer service. This is particularly apparent in the functional combination of mass production and an individual approach to customers and their needs. If customers do not have sufficient research and development facilities of their own, the holding can arrange for model applications of its products. Data proving the efficacy of products manufactured and supplied by Contipro Group is supplied as a matter of course. Customers can also test the efficacy of final products based on their own individual requirements.
  
• All the holding’s activities and products have a common denominator – maximum attainable quality. Quality is the holding’s most important and most prized asset. Contipro Group holds the quality certificate ISO 9001:2000; its subsidiary pharmaceutical company Contipro C also has ISO 13485:2003 certification and a GMP certificate.
  
• The holding is exceptional not only thanks to the tightly guarded quality of its products. What makes it stand out from other companies in the field is its belief that success in industry, which relies on science to a fair degree, is directly dependent on research. Therefore, the holding ploughs a significant portion of its profits back into research.